Page last updated: 2024-09-21

fluroxene

Description

fluroxene: was heading 1973-94; use ETHERS to search FLUROXENE 1973-94 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9844
CHEMBL ID141446
CHEBI ID134757
SCHEMBL ID60167
MeSH IDM0224679

Synonyms (50)

Synonym
flurossene [dcit]
brn 1745876
fluroxenum [inn-latin]
fluroxene [anaesthetics, volatile]
einecs 206-977-1
fluoromar
ethene, (2,2,2-trifluoroethoxy)-
fluroxene
fluroxeno [inn-spanish]
2,2,2-trifluoroethyl vinyl ether
ether, 2,2,2-trifluoroethyl vinyl
fluroxene (usan)
fluoromar (tn)
D04237
406-90-6
CHEBI:134757
CHEMBL141446
nsc-760364
2-ethenoxy-1,1,1-trifluoroethane
(2,2,2-trifluoroethoxy)ethene
HMS3264D10
AKOS009159362
unii-fo7jha3g03
nsc 760364
fluroxenum
flurossene
fluroxene [usan:inn:nf]
fo7jha3g03 ,
fluroxeno
A825240
2-ethenoxy-1,1,1-tris(fluoranyl)ethane
nsc760364
pharmakon1600-01506162
FT-0609045
fluroxene [inn]
fluroxene [usan]
fluroxene [mi]
fluroxene [who-dd]
CCG-213622
SCHEMBL60167
CS-4763
DTXSID5059957
2,2,2-trifluoroethylvinylether
HY-B1163
AB01563344_01
mfcd00864407
2,2,2-trifluoroethyl vinyl ether, 97%
sr-01000944223
SR-01000944223-1
Q14850809

Drug Classes (1)

ClassDescription
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID26047logBB, log(C brain / C blood)1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Computation of brain-blood partitioning of organic solutes via free energy calculations.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (84.62)18.7374
1990's1 (3.85)18.2507
2000's1 (3.85)29.6817
2010's2 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]